Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients Thomas Powles, Sergio Bracarda, Mei Chen, Elliot Norry, Natalie Compton, Mark Heise, Thomas Hutson, Philipp Harter, Christopher Carpenter, Lini Pandite, Neil Kaplowitz European Journal of Cancer Volume 51, Issue 10, Pages 1293-1302 (July 2015) DOI: 10.1016/j.ejca.2015.03.019 Copyright © 2015 Terms and Conditions
Fig. 1 Cumulative incidence rate of ALT elevations over time for all ALT >3×ULN events (black line), all ALT >8×ULN events (medium grey line), and all ALT >3–8×ULN events (light grey line) in pazopanib-treated patients from the integrated database (N=2080). Abbreviations: ALT, alanine aminotransferase; ULN, upper limit of normal range. European Journal of Cancer 2015 51, 1293-1302DOI: (10.1016/j.ejca.2015.03.019) Copyright © 2015 Terms and Conditions